← KRYS: big moves and long-term fundamentals中文

Krystal Biotech: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 2, 2026 · Reflects: 10-K FY2025, the 10-Q for Q3 2026 and the Q3 2026 release

This page is information, not investment advice.

Sources used most:

1. In one paragraph

Last updated Nov 2, 2026. Reflects the 10-K FY2025, the 10-Q for Q3 2026 and the Q3 2026 release.

Krystal Biotech sells one product: Vyjuvek, a gel containing a modified, non-replicating herpes simplex virus type 1 (HSV-1) that delivers working copies of the COL7A1 gene to the wounds of people with dystrophic epidermolysis bullosa (DEB), a rare genetic disease that makes skin blister and tear. The FDA approved it in May 2023 as the first redosable gene therapy; it is applied weekly. Revenue grew from $50.7M in 2023 to $389.1M in 2025, and Krystal has been profitable since 2024; its small 2023 profit depended on a one-off $100M sale of a priority review voucher. It is using the same vector in eye, lung, skin and cancer programs, and through its subsidiary Jeune Aesthetics in cosmetic injections (section 8).

Vyjuvek revenue by quarter, Q1 2024–Q3 2026 ($M)

Quarterly revenue has risen almost every quarter since launch, to $127.3M in Q3 2026; since mid-2025 the growth has come mostly from Europe and Japan.

Vyjuvek net product revenue ($M)050100150Q1 2024: $45.3MQ2 2024: $70.3MQ3 2024: $83.8MQ4 2024: $91.1MQ1 2025: $88.2MQ2 2025: $96MQ3 2025: $97.8MQ4 2025: $107.1MQ1 2026: $116.4MQ2 2026: $119.2MQ3 2026: $127.3MQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026Vyjuvek net product revenue ($M)050100150Q1 2024: $45.3MQ2 2024: $70.3MQ3 2024: $83.8MQ4 2024: $91.1MQ1 2025: $88.2MQ2 2025: $96MQ3 2025: $97.8MQ4 2025: $107.1MQ1 2026: $116.4MQ2 2026: $119.2MQ3 2026: $127.3MQ1'24Q3'24Q1'25Q3'25Q1'26Q3'26

Q4 figures are our calculation: full year minus the first nine months.

Krystal Biotech 10-Ks FY2024 and FY2025, 10-Qs 2024–2026 (company XBRL data).
Show the data table
Quarter Revenue ($M)
Q1 2024 45.3
Q2 2024 70.3
Q3 2024 83.8
Q4 2024 91.1
Q1 2025 88.2
Q2 2025 96.0
Q3 2025 97.8
Q4 2025 107.1
Q1 2026 116.4
Q2 2026 119.2
Q3 2026 127.3
  • Approvals: US (May 2023; from birth since September 2025), European Union (April 2025) and Japan (July 2025); launched in Germany in August 2025 and in France (under an early-access reimbursement program) and Japan in October 2025 (10-K; 10-Q).
  • Gross margin was 94% in Q3 2026 (Q3 release).
  • Krystal has no debt and held about $1.19B of cash and investments at Sep 30, 2026 (10-Q).

2. Story so far

Last updated Nov 2, 2026. Reflects filings and releases through Nov 2, 2026.

In short: Krystal spent its first seven years developing Vyjuvek, funded by share sales, then turned profitable within a year of its 2023 approval. Since 2025 it has launched in Europe and Japan, while several pipeline milestones have moved later. In November 2026 it authorized its first buyback.

Date Milestone Source
Apr 2016 Krystal starts operations; it becomes a Delaware corporation in March 2017 10-K FY2025
Apr 2019 Incorporates Jeune Aesthetics, a wholly owned subsidiary for cosmetic skin studies 10-K FY2025
Feb and Dec 2021 Sells 5.1M shares in two public offerings at $65 and $75 10-K FY2021
Apr 2022 Settles a 2020 trade-secrets lawsuit by PeriphaGen for $75M in total, receiving a licence for dermatology uses; fully paid by 2025 10-K FY2025
May 19, 2023 ★ FDA approves Vyjuvek, the first redosable gene therapy; Krystal sells 1.73M shares at $92.50 days later and, in Q3, sells the priority review voucher it received for $100M 10-K FY2023
2024 First full year of sales: revenue $290.5M, net income $89.2M 10-K FY2025
Q1 2025 Krystal and some employees receive Department of Justice subpoenas about a Vyjuvek genetic-testing program and commercial practices 10-K FY2025
Apr–Oct 2025 ★ European approval (April) and Japanese approval (July); launches in Germany (August), France under early access, and Japan (October) 10-K FY2025
Jul 24, 2025 Jeune reports results from PEARL-2, a 19-person placebo-controlled trial of KB304 for upper-chest wrinkles (section 8) Jeune release
Sep–Oct 2025 US label extended to patients from birth; FDA grants platform technology designation to the vector used in KB801 10-K FY2025
Nov 2, 2026 ★ Q3 results: revenue up 30%; results and enrollment milestones for four programs move into 2027; $400M buyback authorized; the stock falls 11%. Start of our coverage: Why Krystal Biotech stock fell Q3 release

3. Latest quarter: did the story change?

Last updated Nov 2, 2026. Reflects Q3 2026 (release and 10-Q, Nov 2, 2026) against Q2 2026.

Bottom line: According to its Nov 2 release and 10-Q, Krystal grew revenue 30% and stayed solidly profitable, but almost all the growth came from Europe and Japan. Several pipeline milestones moved into 2027, and the company cut its 2026 expense forecast.

Driver Last quarter → this quarter Management: before → now Signal
Vyjuvek revenue Q2 $119.2M (+24%) → Q3 $127.3M (+30%); net income $54.8M → $63.1M No revenue guidance → no revenue guidance Better
US revenue Q2 $91.6M (−4.6%) → Q3 $95.3M (+2.6%) Over 730 US reimbursement approvals (Q2) → over 760 (Q3) Watch
Europe and Japan revenue Q2 $27.6M → Q3 $32.0M (+16% on the quarter), 25% of revenue German pricing talks ongoing; Italy launch expected before year-end (Aug 3) → pricing talks complete in Germany and Italy; Italy launch early 2027 (Nov 2) Better
Pipeline timing KB803 results Q4 2026; KB801 enrollment complete by year-end (Aug) → both in 2027 KB407 interim results by year-end (Aug) → first half 2027 Worse
2026 expense guide (research and development (R&D) plus selling, general and administrative (SG&A) expenses, excluding stock pay; company measure) — $175–195M (earlier in 2026) → $155–165M (Nov 2) Watch

Sources: Q2 2026 release, 10-Q Q2 2026, Q3 2026 release, 10-Q Q3 2026. Regional figures and growth rates are our calculation1.

Unresolved questions: whether US sales grow again, and what the lower expense forecast says about the pace of the trials.

4. Buybacks vs real dilution (5 years)

Last updated Nov 2, 2026. Reflects the equity statements in the 10-Ks for FY2021, FY2023 and FY2025 and the 10-Q for Q3 2026.

Dilution in one line: shares outstanding rose about 48% from Dec 31, 2020 to Dec 31, 2025, about 8.2% a year. If you owned 1% of Krystal at the end of 2020, you’d own about 0.68% at the end of 2025 without buying more2. There were no buybacks. Our scale: High (over 5% a year).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2020 to Dec 31, 2025FY2021 +27.9%, FY2022 +2.2%, FY2023 +9.6%, FY2024 +2.0%, FY2025 +1.4%. Total +48.1% since Dec 31, 2020.0%+10%+20%+30%+40%+50%FY2021: +27.9% in the period; +27.9% since Dec 31, 2020+27.9%FY2021FY2022: +2.2% in the period; +30.7% since Dec 31, 2020+2.2%FY2022FY2023: +9.6% in the period; +43.2% since Dec 31, 2020+9.6%FY2023FY2024: +2.0% in the period; +46.1% since Dec 31, 2020+2.0%FY2024FY2025: +1.4% in the period; +48.1% since Dec 31, 2020+1.4%FY2025+48.1%since Dec 31, 2020

Change in the period Total since Dec 31, 2020

Shares outstanding at period end (all classes): 19.7M on Dec 31, 2020, 29.2M on Dec 31, 2025, +48.1% (our calculation). A bar below zero means the count fell (net buybacks).

Latest quarter-end (Sep 30, 2026): 29.6M shares, +1.5% since Dec 31, 2025.

Shares outstanding (one class of common stock).

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
FY2025 (Dec 31, 2025)29.2M+1.4%—$55M14%
FY2024 (Dec 31, 2024)28.8M+2.0%—$49M17%
FY2023 (Dec 31, 2023)28.2M+9.6%—$40M79%
FY2022 (Dec 31, 2022)25.8M+2.2%—$33M—
FY2021 (Dec 31, 2021)25.2M+27.9%—$15M—
FY2020 (Dec 31, 2020)19.7M——$3M—

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

How we calculated this

Most new shares were sold for cash in 2021–2023, before Vyjuvek earned money; the rest came from employee stock plans.

Bridge (millions of shares) Shares
Start (Dec 31, 2020) 19.71
+ Shares sold for cash (2021–2023: public offerings, at-the-market sales and a private placement) +7.51
+ Employee stock plans and other issuance (our calculation, the remainder) +1.97
End (Dec 31, 2025) 29.19
  • At Sep 30, 2026, 29.63M shares were outstanding, 1.5% more than at the end of 2025 (10-Q)2.

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2021 — — — 5.34M $70.44 (our calculation) $376.2M (gross) 10-K FY2021
2022 — — — 0.43M $69.00 $30.0M (gross) 10-K FY2023
2023 — — — 1.73M $92.50 $160.0M 10-K FY2023
2024 — — — — — — 10-K FY2025
2025 — — — — — — 10-K FY2025
2026 to date (Jan–Sep) — — — — — — 10-Q Q3 2026

Krystal sold 7.5M shares for about $566M from 2021 to 2023, at prices from $65 to $92.50, and none since; it has not yet bought back shares3.

Basis and details
  • 2021: public offerings of 2,211,538 shares at $65 (Feb 1) and 2,866,667 at $75 (Dec 3), plus 262,500 at-the-market (ATM) shares at a weighted average of $66.50. 2022: 434,782 ATM shares at a weighted average of $69.00. 2023: 1,729,729 shares at $92.50 in a private placement on May 22–23, for net proceeds of $160.0M (10-K FY2021; 10-K FY2023).
  • Krystal has had no stock split in the period. Employee plans are excluded from “sold for cash”.
  • Buybacks: the board authorized up to $400M on Nov 2, 2026; Krystal expects to buy “opportunistically over the next two years”. The program has no expiration date and does not oblige Krystal to buy any shares (Q3 release; 10-Q).
  • For reference, Nasdaq reports a $295.90 close on Nov 2, 2026 (Nasdaq).
Stock-based pay 2021 2022 2023 2024 2025 9M 2026
$M 15 33 40 49 55 42
% of revenue (our calculation)4 n/m n/m 79% 17% 14% 11%

Stock-based pay has risen every year in dollars but fallen as a share of revenue since Vyjuvek launched; “n/m” means Krystal had no revenue (10-K FY2025; 10-Q).

Insider transactions: Form 4 filings show net selling and no open-market buying in the 12 months to Nov 2, 2026: about 381,000 shares, worth about $105M (our calculation)5.

  • Chief Executive Krish Krishnan and his spouse, President of R&D Suma Krishnan, each sold 125,000 shares (about $34.3M each) under Rule 10b5-1 plans, prearranged trading plans; each filing says the spouse’s transactions are reported separately, so we count both.
  • Directors Daniel Janney (71,964 shares, about $19.4M) and Dino Rossi (43,950; about $13.2M) were the next-largest sellers; the chief accounting officer and general counsel sold 13,250 and 1,642 shares.
  • About 88% of the shares sold were under 10b5-1 plans; Rossi’s sales were not.
Insider details
  • Other entries are option exercises, shares withheld for taxes and gifts.
  • The sales equal about 1.3% of the 29.6M shares outstanding on Oct 28, 2026 (our calculation). Krish Krishnan’s plan was adopted on Sep 4, 2025 and runs to Dec 4, 2026 at the latest (Form 4).
  • We read all 24 Form 4 filings filed from Dec 5, 2025 to Sep 16, 2026, the latest before Nov 2, 2026; the six filed on Sep 16 report director share awards, not sales (filings list).

5. Profit vs cash (latest FY and TTM)

Last updated Nov 2, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026. TTM = the four quarters to Sep 30, 2026 (our calculation)6.

Free cash flow was 92% of net income in 2025 and 138% in the 12 months to September 2026 (our calculation). The 2025 profit included a one-off tax gain and its cash flow a final legal payment; from 2026 Krystal records a normal tax charge, which lowers reported profit7.

$M FY2025 TTM to Sep 30, 2026 (our calculation)
Revenue 389.1 470.0
Net income 204.8 225.2
Operating cash flow 200.9 323.9
Capital spending −12.0 −13.8
Free cash flow (our calculation)7 188.9 310.1

Helps future profit or cash:

  • Stock-based pay ($54.5M in 2025) is a cost in profit but not in cash; it shows up as dilution instead (section 4).

Hurts future profit or cash:

  • Receivables used $22.1M of cash in 2025: sales recorded but not yet collected. One customer accounted for 61% of receivables at Sep 30, 2026 (10-Q).
  • Rebates still to be paid: accrued rebates and fees rose by $21.3M in 2025, which raised cash flow that year but will be paid out later.
  • Taxes: Krystal now records tax expense; Q3 2026 pretax income was $80.1M and net income $63.1M (10-Q).

One-off / no lasting effect:

  • Tax gain: deferred taxes reduced 2025 operating cash flow by $22.8M against net income, mainly after a one-time release of a tax valuation allowance that lifted 2025 net income without bringing in cash. In Q3 2025, an income-tax benefit of $31.4M lifted net income to $79.4M (10-K; 10-Q).
  • PeriphaGen settlement: $31.25M paid in 2025, the last of $75M in total; the $25M upfront payment was expensed in 2022 and the milestone charges in 2023 ($12.5M) and 2024 ($37.5M) (10-K FY2023; 10-K).
  • In 2023, the $100M sale of the priority review voucher lifted net income to $10.9M, while operating cash flow was −$88.8M (10-K FY2023).
The raw reconciling items (FY2025)

From the cash flow statement (10-K): stock-based pay $54.5M; deferred income taxes −$22.8M; realized gains on investments −$6.0M; working capital: receivables −$22.1M, accrued rebates and fees +$21.3M, litigation settlement paid −$31.25M, prepaid income taxes −$12.4M; plus depreciation and other smaller items.

Self-funding

Funding: how long without new money? Self-funding: $310.1M of free cash flow in the 12 months to Sep 30, 2026 (our calculation)7; no debt, against $1.19B of cash and investments8.

Funding details
  • As of Sep 30, 2026: cash and cash equivalents $462.8M, short-term investments $449.0M and long-term investments $282.3M (corporate bonds and US agency securities) (10-Q)8.
  • This is based on past cash flow; spending plans can change it.

Extends the runway:

  • None committed. Krystal had a $150M at-the-market share sale program that it never used; it expired with its shelf registration on Apr 6, 2026, and Krystal said it did not intend to renew it (10-K).

Shortens the runway:

  • Buybacks are discretionary: up to $400M under an authorization with no expiration date; management expects to buy opportunistically over the two years from Nov 2, 2026 (Q3 release; 10-Q).
  • 2026 combined R&D and SG&A expenses, excluding stock-based pay, are guided at $155–165M (Q3 release).

Conditional:

  • The Department of Justice inquiry: Krystal says it cannot estimate any possible loss (10-Q).

6. Customer and contract exposure

Last updated Nov 2, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026.

Krystal depends on one product and, in the US, on one specialty pharmacy: a single US customer accounted for about 75% of 2025 product revenue. The US still provides about three-quarters of sales, but almost all recent growth has come from Europe and Japan.

Vyjuvek revenue by region, first nine months of 2026 ($M)

The US provided about three-quarters of revenue; Europe and Japan, where Vyjuvek launched in late 2025, the rest.

United StatesUnited States: 274.4 (Revenue, Jan–Sep 2026 ($M))274.4EuropeEurope: 63.2 (Revenue, Jan–Sep 2026 ($M))63.2JapanJapan: 25.3 (Revenue, Jan–Sep 2026 ($M))25.3United StatesUnited States: 274.4 (Revenue, Jan–Sep 2026 ($M))274.4EuropeEurope: 63.2 (Revenue, Jan–Sep 2026 ($M))63.2JapanJapan: 25.3 (Revenue, Jan–Sep 2026 ($M))25.3
Krystal Biotech 10-Q for Q3 2026, note 3 (product revenue by region).
Show the data table
Region Revenue ($M)
United States 274.4
Europe 63.2
Japan 25.3
Customer and contract details
  • Customers: one US customer generated about 75%, 87% and 100% of product revenue in 2025, 2024 and 2023 (10-K, note 3). Krystal sells through a limited number of specialty pharmacies, which mix the gel for use at home or in a clinic, and a limited number of hospitals and distributors (10-K).
  • In 2024, a cybersecurity incident at Krystal’s specialty pharmacy delayed reimbursement approvals and hurt product revenue (10-K, risk factors).
  • US sales: $274.4M in the first nine months of 2026, down from $277.1M a year earlier; Krystal attributes revenue growth to launches in Europe and Japan, “partially offset by a reduction in United States VYJUVEK sales” (10-Q)1.
  • Pricing: negotiations are complete in Germany and Italy; decisions are expected in Spain later in 2026 and in France no earlier than 2027, where Vyjuvek has been sold since October 2025 under an early-access reimbursement program; applications are filed or planned in Australia and Switzerland (Q3 release; 10-Q).
  • Government inquiry: in Q1 2025, Krystal and some employees received Department of Justice subpoenas for documents about its sponsored genetic-testing program for Vyjuvek and related commercial practices; Krystal is cooperating (10-Q).
  • Shareholder suit: a September 2025 derivative complaint in Delaware over director pay was settled; the court approved the settlement and dismissed the action on Sep 15, 2026, and Krystal adopted five years of governance reforms (10-Q).

7. Krystal’s strategy for long-term growth

Last updated Nov 2, 2026. Reflects the 10-K FY2025, the 10-Q and release for Q3 2026, and the Jeune releases.

Krystal’s business rests on one product in a rare disease, whose US sales were about 1% lower in the first nine months of 2026 than a year earlier. Its strategy is to sell Vyjuvek in more countries and to reuse the same redosable HSV-1 vector for other genes and tissues: the eye, the lungs, other skin diseases, cancer and, through Jeune, cosmetics. None of those programs is approved, and several have taken longer than planned.

Pressure on the core business

The filings show a single product facing competing treatments, US sales that fell about 1% over the first nine months of 2026 despite growing again in Q3, and patents that run into the 2030s.

  • One product: Vyjuvek is Krystal’s only source of product revenue (10-K).
  • US demand: US sales fell about 1% in the first nine months of 2026, after a 4.6% drop in Q2 and a 2.6% rise in Q3; Krystal reported over 760 US reimbursement approvals in Q3, up from over 730 in Q2 (10-Q; Q3 release; Q2 release).
  • Competition: Krystal’s 10-K names Abeona Therapeutics’ Zevaskyn, a gene-corrected skin graft therapy approved by the FDA in 2025, and Chiesi’s Filsuvez (birch triterpenes), a palliative gel approved in 2023 (10-K).
  • Patents and exclusivity: Krystal’s US patents on its delivery platform and on Vyjuvek expire on Dec 28, 2036 (before any extensions). Separately, US law bars the FDA from approving a biosimilar until 12 years after the original product’s licence, which for Vyjuvek would be May 2035 (our calculation from the 10-K’s description). Krystal also has orphan drug exclusivity in the US, EU and Japan (10-K).

The strategy in management’s words

Management describes Vyjuvek’s cash flow as funding the pipeline and, now, buybacks.

  • Chief Executive Krish Krishnan: “Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline … Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders” (Q3 release).
  • One vector, many uses: Krystal’s programs use the same engineered HSV-1 vector to carry different genes, applied as a gel (skin), eye drops (KB803, KB801), inhaled (KB407 for cystic fibrosis, KB408 for alpha-1 antitrypsin deficiency, KB707 for lung cancer) or injected (KB113 for basal cell carcinoma; Jeune’s cosmetic products) (Q3 release).
  • Regulatory leverage: in October 2025, the FDA granted platform technology designation to the vector used in KB801; Krystal says this offers development and manufacturing efficiencies (10-K).
  • Deals: Krystal has made no acquisitions; its largest outside cost was the $75M PeriphaGen settlement, which came with assets and a dermatology licence (10-K).
  • Cosmetics: Krystal keeps the aesthetics work in a separate subsidiary that, according to a July 2025 Jeune presentation, was “purpose-built … to allow optionality for value-creating events”. In September 2026, Krishnan said Krystal had paused Jeune to focus on its rare-disease trials and was looking for a partner (section 8).

Is it working?

Vyjuvek’s international launches are adding revenue; the pipeline has produced no revenue yet, and its timelines have slipped.

  • Revenue: $50.7M (2023), $290.5M (2024), $389.1M (2025), $470.0M in the 12 months to September 2026 (our calculation)6. Europe and Japan made up 25% of Q3 2026 revenue1.
  • Profit: net income of $204.8M in 2025 and $173.8M in the first nine months of 2026 (10-K; 10-Q).
  • Pipeline: no other product has been filed for approval. On Nov 2, 2026, Krystal moved expected KB803 and KB407 results into 2027, and expected enrollment milestones for KB801 and a KB707 lung cancer group into 2027; it cited narrow eligibility criteria and the difficulty of a placebo-controlled trial when an approved treatment exists for KB801 (Q3 release; Q2 release).
  • Early data: KB707 with pembrolizumab showed a 31% response rate in advanced lung cancer in an interim analysis presented in May 2026; KB113 shrank more than 80% of assessed basal cell carcinoma lesions in a three-patient pilot (Q3 release).
  • Spending: R&D was $58.0M in 2025, about 15% of revenue (our calculation), and $44.7M in the first nine months of 2026 (10-K; 10-Q).

Strategy: what to watch

  • Whether US Vyjuvek sales sustain Q3’s return to growth; the Italy launch expected in early 2027; and French pricing talks, expected to end no earlier than 2027 (France launched under early access in October 2025).
  • The first registrational readouts (from studies designed to support an approval application) outside DEB skin wounds: KB803 (early 2027) and KB801 (2027).
  • How much of the $400M buyback Krystal uses, and at what prices.
  • The outcome of the Department of Justice inquiry.

8. Jeune Aesthetics: the cosmetic gene-therapy subsidiary

Last updated Nov 2, 2026. Reflects the 10-K FY2025, the 10-Q and release for Q3 2026, Jeune releases and presentations filed with the SEC (2021–2025), management’s comments on the Q2 2025 call and at a September 2026 conference, ClinicalTrials.gov records and the Vyjuvek FDA label.

Jeune is a small, early-stage part of Krystal, and it is on hold: in September 2026 Chief Executive Krish Krishnan said Krystal had “paused Jeune” to focus on its rare-disease trials, and that it wants a partner. Jeune has no revenue, and its direct trial costs were about $1.1M in 2025 out of $58.0M of R&D. Its products are investigational. The efficacy and safety data so far come from small, company-reported Phase 1 trials with at most about nine months of follow-up. We found no peer-reviewed publication or posted registry results, and the FDA has not approved any of its products. Jeune expects to start a Phase 2 trial of its lead candidate, KB304, in 2027.

What the business is and how it fits

Jeune uses Krystal’s vector to deliver genes for skin proteins by injection into the skin of healthy adults, a cash-pay cosmetic market rather than a disease treatment.

  • Structure: Jeune was incorporated in April 2019 as a wholly owned subsidiary “for the purposes of undertaking preclinical and clinical studies for aesthetic skin conditions” (10-K). A July 2025 Jeune presentation says Jeune holds an exclusive licence to Krystal’s HSV-1 platform “for cash pay markets” and relies on Krystal for R&D, manufacturing, regulatory and other functions (Jeune presentation, Jul 2025).
  • Products: KB301 delivers two copies of the COL3A1 gene, for type III collagen. KB304, now the lead program, delivers two copies of COL3A1 and one of the gene for elastin, the protein that gives skin its stretch. Both are injected into the skin (10-K). The presentation also lists three earlier-stage candidates, KB302, KB303 and KB305, with no indication chosen (Jeune presentation).
  • Economics: no revenue. Direct costs: KB301 $0.18M and KB304 $0.96M in 2025; KB304 $52,000 in the first nine months of 2026, down from $906,000 a year earlier ($23,000 in Q3) (10-K; 10-Q). Jeune’s total costs, including staff, are not disclosed.
  • Strategy: Jeune’s presentation says the subsidiary “was purpose-built … to allow optionality for value-creating events during clinical development”; it does not say what such events would be (Jeune presentation). Its chief executive, Marc Forth, previously ran AEON Biopharma, which developed a botulinum toxin (Jeune presentation).
  • Market and competition: Jeune cites 9.9M cosmetic neurotoxin and 6.3M filler injections (excluding lip fillers) in the US (American Society of Plastic Surgeons, 2024) and says no injectable is FDA-approved for the décolleté (upper chest) (Jeune presentation). Krystal’s 10-K lists hyaluronic acid and botulinum toxin products from AbbVie, Revance, Merz, Galderma and others as competitors (10-K).
  • Patents: Krystal lists patents on HSV vectors carrying “cosmetic proteins” in the US, Japan, Australia and elsewhere, expiring Apr 26, 2039 (10-K).
  • Spin-out plan: on the Q2 2025 call (Aug 4, 2025), Krishnan said Jeune’s chief executive and finance chief were “diligently working towards getting [Jeune] financed and spun out”, and that “by the middle to the end of 2026, we’re expecting [Jeune] to be a separate subsidiary” (as reported in Equibles’ call transcript). The Q3 2026 10-Q still describes Jeune as wholly owned, and we found no filing on outside financing, a partner or a spin-off (10-Q).
  • Paused: asked about Jeune at the Cantor Fitzgerald healthcare conference on Sep 10, 2026, Krishnan said: “We wanted to focus as a company, and we paused Jeune. Our goal is to get Jeune resumed next year to do the phase II study, but definitely start looking for a partner who can help us even potentially do the phase II study.” He gave the upcoming registrational trials in cystic fibrosis as the reason and said: “It’s not the data that made us stop the thing … It’s just a question of bandwidth.” He added that “we definitely need a partner to launch something in aesthetics” (as reported in Stock Analysis’s conference transcript). Krystal’s releases since then still say only that Jeune “expects to initiate a Phase 2 study … in 2027” (Q3 release).

Planned Phase 2 start dates have moved several times:

Announcement Plan as stated Source
Mar 2022 KB301 Phase 2 testing “later this year” Jeune release
Nov 2022 KB301 Phase 2 (then called PEARL-2) in the first half of 2023 Jeune release
Aug 2024 KB301 Phase 2 in the décolleté, “expected to start next year” Jeune release
Jul 2025 KB304, now prioritized: Phase 2 goal first half of 2026 Jeune release
Feb 2026 and Nov 2026 KB304 Phase 2 expected to start in 2027 10-K; Q3 release
Sep 10, 2026 Jeune “paused”; goal to resume “next year” and find a partner Krishnan at the Cantor conference, as reported in Stock Analysis’s transcript

Does it work for cosmetic uses? What the trial data show

Jeune reported placebo comparisons in two studies, KB301’s PEARL-1 Cohort 2 and KB304’s PEARL-2, with better ratings in the treated groups over one to three months; the KB301 extension and Cohorts 3 and 4 were open-label studies without control groups, while Cohort 1 compared treated skin with untreated or saline-injected sites in the same people. Jeune itself cautions that preliminary Phase 1 findings from small samples with limited follow-up may not predict later results, and the sources we reviewed report no independent replication.

Study (product) Design People Measures and timing Company-reported results
PEARL-1 Cohort 1 (KB301) Three dose levels injected twice, 30 days apart, into buttock skin; biopsies; untreated or saline sites as controls 7 healthy adults Safety; COL3A1 gene RNA in skin biopsies two days after dosing “Well tolerated”; RNA from the gene detected at the two higher doses and after the second dose; no vector detected in blood, urine or skin swabs; presented at a 2021 dermatology meeting
PEARL-1 Cohort 2 (KB301) Randomized 2:1, double-blind; KB301 and saline placebo on matching sites of the same person 27 enrolled (26 women, average age 65); 4 dropped out Registered main outcome: safety. Aesthetic ratings at Visit 6, about eight weeks after the first injection; above-knee skinfold thickness at Visit 5, about six weeks after Above the knee: subject-rated responders at 41.9% of 31 KB301-treated sites vs 20.0% of 15 placebo sites; skinfold thickness +1.74 mm vs +0.67 mm. Lower cheek (19 high-dose vs 9 placebo sites): mean subject satisfaction score up 1.9 vs 0.9 points at Visit 6. On the cheeks, blinded independent reviewers “did not show clinical separation” from placebo
PEARL-1 extension (KB301) Open label; no placebo comparison 10 from Cohort 2: 13 previously treated lower cheeks assessed at about seven and eight months, 10 at about nine months About 7–9 months after the last dose Mean subject score 1.6–1.85 points above baseline; 62–70% of cheeks responders
PEARL-1 Cohorts 3 and 4 (KB301) Open label, single arm; no control group Upper chest: 20 enrolled, 18 assessed; eye corners: 13 enrolled, 12 assessed Global Aesthetic Improvement Scale (GAIS), an investigator’s or participant’s rating of overall change in appearance, at 1 and 2 months Upper chest: 94% improved by at least one point at 2 months (investigator); eye corners: 75%
PEARL-2 (KB304) Randomized 2:1, double-blind, saline placebo; three treatments two weeks apart; one site 19 women (12 KB304, 7 placebo); 18 assessed; median age 62; skin types I–IV Registered main outcome: safety, up to four months. GAIS and a satisfaction questionnaire at 1, 2 and 3 months after treatment At 3 months: 100% of KB304 subjects improved by investigator rating vs 28.6% on placebo; 72.7% vs 14.3% by subjects’ own rating; 81.8% vs 14.3% more satisfied

Sources: Cohort 2 release, Mar 2022; Cohort 2 presentation; extension release, Nov 2022; Cohorts 3–4 release, Aug 2024; PEARL-2 release, Jul 2025; PEARL-2 presentation; 10-K.

What is not known, and how to read these numbers
  • Size: KB304’s placebo-controlled result rests on 11 treated and 7 placebo participants, so each KB304 participant is about 9 percentage points; for example, 72.7% is 8 of 11 (our calculation)9. Jeune described the PEARL-2 differences as “statistically significant” but its release and presentation give no p-values or statistical tests.
  • Measures: GAIS asks the investigator or participant whether appearance improved overall; it is a global rating rather than a wrinkle measurement. For Phase 2, Jeune developed a décolleté-specific photographic scale (JDWS) and says it has aligned with the FDA on it (10-K).
  • Durability: the longest follow-up reported is about nine months, open-label, in 10 people (KB301); KB304 results go to three months (Nov 2022 release; Jul 2025 release). Jeune said in 2024 that some Cohort 4 participants were redosed and data collection was ongoing; we found no published results.
  • Independent review: neither study has posted results on ClinicalTrials.gov. Both records, last updated May 13, 2025, list the studies as active, not recruiting: PEARL-1 with 85 people enrolled across cohorts and completion estimated for May 31, 2029; PEARL-2 with 19 enrolled and completion estimated for August 2025; the records do not confirm actual completion (PEARL-1 registry; PEARL-2 registry). Our PubMed search on Nov 2, 2026 found no peer-reviewed paper on KB301 or KB304 (PubMed); that does not rule out publications we did not find.
  • Who ran the trials: ClinicalTrials.gov lists one site for PEARL-2, Steve Yoelin Medical Associates in Newport Beach, California, and no data monitoring committee (PEARL-2 registry); Dr. Yoelin is a PEARL-1 principal investigator quoted in Jeune’s releases (Aug 2024 release).
  • Registry labels: ClinicalTrials.gov lists PEARL-2 as Phase 1/2 (the company calls it Phase 1) and PEARL-1, across all its cohorts, as non-randomized with no masking, unlike the company’s description of Cohort 2 as randomized and double-blind (PEARL-1 registry; PEARL-2 registry).
  • Unreported participants: the PEARL-1 cohorts Jeune has described total 67 people (7 + 27 + 13 + 20), against 85 enrolled in the registry; we found no data on the other 18 (our calculation).
  • Comparisons: no trial has compared KB301 or KB304 with existing treatments such as fillers or toxins.
  • Jeune’s own release cautions that “preliminary clinical data from a Phase 1 trial with a small sample size and limited follow-up may not predict results in later-stage studies” (Jul 2025 release).

Is it safe for cosmetic use? What has been reported

Jeune’s releases describe mostly transient, mild or moderate adverse events, largely injection reactions, and report no drug-related serious adverse events in the cohorts cited. Jeune has not published a pooled safety analysis; the two registry records list 104 people enrolled, including placebo recipients. The Jeune reports we reviewed give follow-up of up to about nine months for KB301 and three months for KB304, so long-term safety of repeated cosmetic use is not yet established; Jeune cautions that limited Phase 1 follow-up may not predict later findings.

  • KB304 (PEARL-2): Jeune’s presentation counts 60 adverse events: 24 mild, 36 moderate, none severe, life-threatening or fatal; 43 after the first dose, 11 after the second and 6 after the third. The most common were itching (pruritus), muscle pain (myalgia) and skin reactions, lasting a median of two to four days. The summary does not split the events between the KB304 and placebo groups (Jeune presentation).
  • KB301 (PEARL-1): in Cohort 2, Jeune reported that 91–100% of injection-site adverse events on treated sites were mild, depending on the site, and that they resolved within three to five days. It also reported systemic events linked to drug or placebo: mild body ache (4), fatigue (4), headache (2) and chills (2), and moderate muscle pain on one side of the body (placebo side, 1) (Cohort 2 presentation). In Cohort 1, it reported no vector detected in blood, urine or skin swabs (Mar 2021 release). In Cohorts 3 and 4, events were “primarily injection associated, mild-to-moderate, and transient”, with no drug-related serious adverse events (10-K). Jeune’s August 2024 presentation counts 54 local reactions in the 13-person eye-corner group (25 grade 1, 29 grade 2, mostly swelling) and 109 in the 20-person upper-chest group (90 grade 1, 19 grade 2, mostly redness and itching), plus possibly related systemic events in 2 and 4 people, including chills, headache, muscle aches, dizziness, vomiting and swelling of the hands (Cohorts 3–4 presentation).
  • Immune response: the only antibody data released for the cosmetic programs are from Cohort 1, where Jeune reported “no clinically significant changes in anti-drug antibodies” in six people followed to day 90 (Mar 2021 release). We found no antibody data for the later cohorts or PEARL-2. Repeat dosing matters because Jeune reported effects lasting up to about nine months, so a product would presumably be given again; for Vyjuvek, the label reports that 6 of 8 patients without prior HSV-1 antibodies developed them by week 26, and that antibodies to the protein the gene produces (type VII collagen) were detected in 13 of 18 patients with matched samples from the start and end of the study; it says data are “limited” for assessing their effect (Vyjuvek label).
  • The vector in an approved product: in Vyjuvek’s FDA label, the vector is described as replication-deficient and non-integrating (it does not copy itself or enter the patient’s DNA). The most common side effects in the 31-patient DEB trial were itching, chills, redness, rash, cough and runny nose, and the label warns caregivers and close contacts to avoid direct contact with treated wounds. Vyjuvek is applied to wounds, not injected into healthy skin (Vyjuvek label).
  • Different risk context: Jeune’s participants are healthy adults seeking a cosmetic result. Krystal’s 10-K notes that Phase 1 trials of gene therapies “are typically conducted in patients rather than healthy volunteers”, and lists “negative public opinion and increased regulatory scrutiny of gene therapy” as a risk (10-K). MIT Technology Review’s Antonio Regalado wrote in 2023 that the project “could lead to a future where gene therapy is given to adults for non-medical enhancement, not just to treat dire health conditions” (MIT Technology Review).
  • What regulators have said: we found no public FDA statement, advisory committee review or published FDA correspondence about KB301 or KB304. The FDA interactions we know of are the company’s descriptions: Cohort 2 enrolled an older age range than is typical in aesthetic trials “due to regulatory feedback”; in November 2022 Jeune cited FDA feedback on its KB301 facial scales; and it later reported alignment with the FDA on the KB304 décolleté wrinkle scale. None of these is an FDA approval (Cohort 2 presentation; Nov 2022 release; 10-K). We found no gene therapy approved by the FDA for a cosmetic use. The closest precedent we found is a cell therapy, Fibrocell’s LAVIV, made from patients’ own skin cells for smile-line wrinkles: in October 2009, an FDA advisory committee voted 11–3 that the data showed it worked and 6–8 against the data showing it was safe; the FDA asked for more data, including a tissue study, and approved it on Jun 21, 2011 (Fibrocell 10-K FY2009; Fibrocell prospectus, Jun 2011). Krystal’s 10-K describes gene therapies as biologics reviewed by the FDA’s Center for Biologics Evaluation and Research, needing an approved Biologics License Application before sale; it does not describe a separate path for cosmetic uses (10-K).

Where it stands with the FDA, and the next readouts

  • Status: no Jeune product is approved and none has been filed for approval. KB304 has completed one Phase 1 trial (10-K). Development is paused, and Krystal is looking for a partner (Krishnan, Sep 10, 2026, as reported in Stock Analysis’s transcript).
  • Not disclosed: the size, design and primary endpoint of the planned Phase 2, or any timeline for an approval application.
  • Next step: Jeune “expects to initiate a Phase 2 study of its lead program KB304 in 2027” in wrinkles of the décolleté; no date for Phase 2 results has been given (Q3 release).
  • KB301: Krystal is “evaluating aesthetic indications most suitable for advanced clinical development”; it has given no timeline (10-K).
  • Other candidates: in July 2025, Jeune said it expected to move another candidate into clinical trials within 12–24 months (Jeune presentation); the 2026 filings we read give no update.

9. What to watch

Last updated Nov 2, 2026.

Date Item Source
Before end of 2026 Interim results from HALITE-1, the KB111 study in Hailey-Hailey disease, a genetic skin condition Q3 release
Later in 2026 Vyjuvek pricing decision in Spain Q3 release
Q1 2027 FDA meeting on KB111’s results, severity scale and registrational study design Q3 release
Early 2027 Vyjuvek launch in Italy Q3 release
Feb 2027, results shortly after Last patient visit in IOLITE, the registrational KB803 study of eye abrasions in DEB Q3 release
First half of 2027 Interim KB407 results in cystic fibrosis Q3 release
2027 KB801 (EMERALD-1): enrollment complete and top-line results; registrational studies of KB407 and KB111 to start; KB408 interim results; KB304 Phase 2 to start Q3 release
Mid-2027 About 70 patients dosed in the KB707 lung cancer group with chemotherapy Q3 release
2027 (goal) Jeune resumed, a partner found, and the KB304 Phase 2 started Krishnan, as reported in Stock Analysis’s transcript; Q3 release
Next two years from Nov 2, 2026 Buybacks under the $400M authorization, which management expects to make opportunistically; it has no expiration date and no obligation to buy Q3 release; 10-Q
Not scheduled Outcome of the Department of Justice inquiry 10-Q

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Nov 2, 2026$295.90 (Nov 2)$8.8B$7.6B18.7×16.1×38.9×28.3×+26%66%$1.2B12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 2, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition.

Notes and calculations

  1. Revenue by region (10-Q, note 3). Q3 2026: US $95.323M, Europe $23.256M, Japan $8.762M, total $127.341M; Q3 2025: US $92.920M, Europe $4.880M. US growth: 95.323 ÷ 92.920 − 1 = 2.6%. Europe and Japan: $32.018M ÷ $127.341M = 25%. Q2 2026: US $91.633M vs $96.042M (−4.6%); Europe $19.283M + Japan $8.306M = $27.589M; Q3 vs Q2 for Europe and Japan: 32.018 ÷ 27.589 − 1 = 16% (10-Q Q2 2026, note 3). Nine months: US $274.445M vs $277.145M (−1.0%). Shares of nine-month revenue: 274.445, 63.216 and 25.259 ÷ 362.920 = 75.6%, 17.4%, 7.0%. ↩ ↩2 ↩3

  2. Balance-sheet counts: 19,714,220 at Dec 31, 2020 and 29.192M at Dec 31, 2025. Growth = 29.192 ÷ 19.714 − 1 = 48.1%; annual rate = (29.192 ÷ 19.714)^(1 ÷ 5) − 1 = 8.2%; ownership = 1% × 19.714 ÷ 29.192 = 0.675%. Shares sold for cash: 2,211,538 + 2,866,667 + 262,500 + 434,782 + 1,729,729 = 7,505,216. Remainder (employee plans and other): 29.192M − 19.714M − 7.505M = 1.97M. Sep 30, 2026: 29.631M ÷ 29.192M − 1 = 1.5%. ↩ ↩2

  3. Gross amounts: 2,211,538 × $65 + 2,866,667 × $75 + 262,500 × $66.50 = $376.2M, over 5,340,705 shares = $70.44 average; 434,782 × $69.00 = $30.0M; 1,729,729 × $92.50 = $160.0M. Total ≈ $566M. ↩

  4. Stock-based pay ÷ revenue: $39.9M ÷ $50.7M = 79%; $49.1M ÷ $290.5M = 17%; $54.5M ÷ $389.1M = 14%; $41.7M ÷ $362.9M = 11% (9M 2026). 2021: $15.3M; 2022: $33.2M; no revenue in either year (company XBRL data from the 10-Ks and 10-Q). ↩

  5. Sum of code S transactions on the 18 Form 4 filings with sales, filed Dec 5, 2025 to Sep 4, 2026 (transactions from Dec 4, 2025), value = Σ shares × reported weighted-average price: Krish Krishnan 125,000 ($34.27M) + Suma Krishnan 125,000 ($34.27M) + Janney 71,964 ($19.40M) + Rossi 43,950 ($13.18M) + Romano 13,250 ($3.60M) + Thomas 1,642 ($0.54M) = 380,806 shares, $105.27M. Under 10b5-1 plans: 336,856 ÷ 380,806 = 88%. 380,806 ÷ 29,633,472 = 1.3%. ↩

  6. FY2025 − first nine months of 2025 + first nine months of 2026. Revenue: $389.130M − $282.025M + $362.920M = $470.025M. Net income: $204.831M − $153.431M + $173.768M = $225.168M. Operating cash flow: $200.865M − $123.357M + $246.420M = $323.928M. Capital spending: $11.951M − $9.812M + $11.709M = $13.848M (10-K; 10-Q). ↩ ↩2

  7. Free cash flow = operating cash flow − purchases of property and equipment: $200.865M − $11.951M = $188.914M (FY2025); $323.928M − $13.848M = $310.080M (TTM). Ratio to net income: 188.914 ÷ 204.831 = 92%; 310.080 ÷ 225.168 = 138%. Krystal does not report a free cash flow measure. ↩ ↩2 ↩3

  8. $462.841M + $449.010M + $282.301M = $1,194.152M at Sep 30, 2026. The long-term investments are corporate bonds ($105.9M) and US agency securities ($176.4M) (10-Q, investments note). ↩ ↩2

  9. PEARL-2: 11 KB304 and 7 placebo participants assessed. 8 ÷ 11 = 72.7%; 9 ÷ 11 = 81.8%; 10 ÷ 11 = 90.9%; 11 ÷ 11 = 100%; 2 ÷ 7 = 28.6%; 1 ÷ 7 = 14.3%. Group sizes from the PEARL-2 presentation. ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Krystal Biotech: Website (external site)Investor relations (external site)SEC filings (external site)